HUTCHMED (LON:HCM) Reaches New 1-Year High at $346.00

HUTCHMED (China) Limited (LON:HCM) shares reached a new 52-week high during trading on Thursday . The company traded as high as GBX 346 ($4.35) and last traded at GBX 341 ($4.28), with a volume of 146975 shares changing hands. The stock had previously closed at GBX 313 ($3.93).

HUTCHMED Stock Up 7.0 %

The firm has a 50-day moving average price of GBX 272.05 and a two-hundred day moving average price of GBX 268.84. The firm has a market cap of £2.86 billion, a price-to-earnings ratio of 3,130.00 and a beta of 0.68. The company has a debt-to-equity ratio of 11.59, a quick ratio of 2.97 and a current ratio of 2.72.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.